If this message does not appear correctly, click this link

Speeches & Conferences

Nov 28    Upcoming ACTG Asia Pacific Lung Cancer Forum

ACT Genomics will hold ACTG Asia Pacific Lung Cancer Forum on November 28th at Taipei W hotel.  ACT Genomics will invite medical specialists with abundant experiences using NGS multi-gene panel  from Asia Pacific region  to discuss the differences between Western and Eastern lung cancer treatment, and the NGS genetic testing application in lung cancer treatment in Asia. Welcome to join us!

 Nov 10 & 11    Upcoming annual 5th Hong Kong International Oncology Symposium

ACT Genomics has the invaluable opportunity to be one of the sponsors of the 5th Hong Kong International Oncology Symposium (5th HKIOS) on November 10 th and November 11th, 2018 at Hong Kong Science and Technology Park and City University of Hong Kong respectively. The event is co-organized by many first-class medical and academic institutes around the world and in the Guangdong-Hong Kong-Macao Greater Bay area that aims to provide an international platform to foster long-term collaborative relationships among them. The 5th HKIOS will highlight the new core technologies in precision oncology particularly single cell sequencing, artificial intelligence and personalized immunotherapy.  For detailed information and enrollment, please visit https://www.hkpos.org

Image title

 Nov 06   Upcoming Public Medical Talk on Where We Stand with Immunotherapy in Lung Cancers

ACT Genomics is proudly sponsoring a medical talk to be given by Dr. Li Yu Chung, Jacky, consultant and specialist in Clinical Oncology from Hong Kong United Oncology Centre, on lung cancer management and immunotherapy at the Hong Kong Playground Association on November 6th, 2018. Early diagnosis and treatment can help lung cancer patients conquer fear and find new hope.

Image title

 Oct 27   Upcoming Nurse Training Course on Medical Genetics on Cancers

 An educational course for oncology nurses on Medical Genetic for Cancer will take place on October 27th, 2018. The course is co-organized by Hong Kong Society of Medical Genetics and ACT Genomics. Speakers include Dr. Lam Tak Sum, Stephen, Director, Clinical Genetics Service, Hong Kong Sanatorium & Hospital ; Dr. Ho-Ming Luk, Specialist in Genetics and Genomics (Paediatrics); Dr. Wong Hiu Yan, Hilda, Specialist in Medical Oncology and; Dr. Kien-Thiam Tan, PhD,  and Zoey Hsu, patient education executive from ACT Genomics’ Taiwan office. 
Medical genetics is one of the most rapidly evolving areas in Cancer medicine. Precision oncology is a new area of cancer medicine and has introduced a new level of complexity into the practice of cancer risk assessment and management. Oncology providers work at the frontline are responsible to communicate potential benefits, limitations and risks to patients about adopting targeted therapies and accompany diagnostics. This course will help oncology nurses with practical knowledge in providing required counseling to help patients understand rationale and clarify decision of cancer assessment and management between patients and clinical oncologists.

 Oct 19-23    ACT Genomics Presents Precision Medicine Findings in ESMO 2018 Congress

ACT Genomics is proud to be selected for abstract poster presentation during the ESMO 2018 Congress starting from October 19th-23rd at Munich, Germany. In this presentation, we will be presenting our study in exploring the differences between liquid biopsy and tissue-based genomic tests in Asian lung cancer patients to guide treatment selection. Although liquid biopsy tests were able to identify a large proportion of lung cancer patients with indications for targeted therapy, tissue-based testing outperformed liquid biopsies for most therapeutic indications, suggesting that tissue-based testing remains the gold standard for treatment selection.

Image title

 Oct 18   Upcoming Public Medical Talk on Treating Lung Cancer by Frontline Immunotherapies based on Precise Classification and Genetic Analysis

ACT Genomics is proudly sponsoring a medical talk to be given by Dr. Leung Kwong Chuen Angus, specialist in Clinical Oncology from AMO Oncology Centre, on using genomic profiling services for immunotherapy evaluation on lung cancer at the Hong Kong Cultural Center on October 18th, 2018. Dr. Leung will shed light on which lung cancer patients will benefit from immunotherapy.

Image title

 Oct 12   ACT Genomics Gives Plenary Talk in 32nd Best of ASCO Annual Meeting

ACT Genomics is honoured to be invited to give plenary talk at the 32nd Best of ASCO Annual Meeting at EDSA Shangri-La Hotel, Mandaluyong City, Philippines on October 12th, 2018. This event is co-organized by Philippine Society of Medical Oncology and American Society of Clinical Oncology. Dr. Liisa will be presenting the key findings on the ASCO 2018 Annual Meeting:
•Liquid Biopsy to Identify Actionable Genomic Alterations
•Novel Platforms and Clinical Applications for Non-invasive Molecular Testing

Image title

Oct 05   ACT Genomics Precision Cancer Care Talk at Davao, Philippines

ACT Genomics will be organizing a talk entitled “Precision Cancer Care” on October 5th, 2018 at Seda Abreeza Hotel. Dr Allen Lai, Senior VP of ACT Genomics will be the 1stspeaker sharing his insight on “Precision Cancer Care in the Philippines: Diagnostics Perspective”, and followed by Dr. Poon, MSL of ACT Genomics presenting topic on “Precision medicine: Cancer Diagnostic tools, from Past to Present”. We have an invited speaker Dr. Alex Alegrado, Medical Director of ARC Oncology group, he will be discussing topic on “Clinician experience: Real world clinical challenges and the application of genomic information to precision cancer management”. This event will be attended by medical oncologists, hematologists and pathologists in the Davao region.

Oct 04   Precision Cancer Medicine in Drug Development and Clinical Applications Seminar at TRPMA

A seminar entitled “Precision Cancer Medicine in Drug Development and Clinical Applications” will be held by TRPMA and co-held by ACT Genomics  and IQVIA.  ACT Genomics Scientific Officer Dr. Shu-Jen Chen will share cases using biomarkers to accelerate new drug development; Aslan General Manager of Asian-Pacific Area, Dr. Chih-Yi Hsieh will elaborate the experiences of using NGS to conduct basket trial and potential benefit ; Norvatis Taiwan Medical Advisor Dr. Chang will share the trend of using biomarkers in cancer drug development and clinical treatment and the importance of genetic testing integrated in national health insurance. In the panel discussion, the development of precision medicine in cancer drug development, clinical application and policy planning will be discussed.  Welcome to join us!

 Oct 01-04    ACT Genomics Presents Precision Medicine Findings in 2018 World Cancer Congress

ACT Genomics is honoured to have 2 abstracts accepted for e-poster presentation at the 2018 World Cancer Congress (WCC). Hosted by the National Cancer Society of Malaysia, the 2018 Congress will take place from October 1st-4th in the Kuala Lumpur Convention Centre (KLCC). WCC is an initiative of the Union for International Cancer Control (UICC) - which was recognized with Membership Engagement Award - and supports the organization’s purpose statement to unite the cancer community, reduce the global cancer burden, promote greater equity and integrate cancer into the world’shealth and development agenda. WCC is a recognized international conference which encourages effective knowledge transfer and best practices exchange amongst 3,500 cancer control and public health experts from 150 countries.

Image title

Sep 28-30   2018 Taipei International Breast Cancer Symposium was Rounded off

2018 Taipei International Breast Cancer Symposium ended successfully! ACT Genomics was recognized for our booth in company display area and the sponsored talk "Multi-Gene Panel Testing for Hereditary Breast Cancer Syndrome - Clinical Application and Test Interpretation"by Dr. Soo-Chin Lee, the well-known expert from National University Cancer Institute Singapore , endowed the audience with rewarding experiences. We look forward to the next event. 

Image title

Sep 25-29   ACT Genomics Joined National Taiwan University Hospital Delegation Trip to Yogyakarta & Jakarta

ACT Genomics  participated in National Taiwan University Hospital (NTUH) Delegation Trip to Yogyakarta & Jakarta. Commissioned by Taiwan Ministry of Health and Welfare, this delegation trip was expected to bring collaboration opportunity between Indonesia and Taiwan in the medical and  healthcare field. This trip was attend by National Taiwan University Hospital team, National Trade Bureau, Industrial Research Institute and commercial entities.

Sep 27   ACT Genomics  Scientific Talk at National Cancer Hospital, Hanoi

ACT Genomics was honoured to be invited to give a scientific talk at the National Cancer Hospital in Hanoi, Vietnam. Dr. Poon  shared topic on “Promises and Challenges of Next Generation Sequencing in Cancer Management”.

 Sep 21    ACT Genomics Shared Insights in ISPOR-Singapore Annual General Meeting

Dr. Allen Lai, Senior Vice President, ACT Genomics was honoured to present at ISPOR Annual General Meeting 2018. ISPOR Singapore was founded in May 2010, and the ISPOR Singapore Regional Chapter (ISPOR-S) is a critical component chapter of the ISPOR headquartered in the US. Over the past few years, the ISPOR-S has committed to conducting fundamental research and capability-building activities directed towards the promotion of pharmacoeconomics and outcomes research in Singapore; endeavored to facilitate scholarly and engaging discussion on far-reaching topics, such as personalized medicine and stakeholder management in health technologies, among researchers, biopharmaceutical companies, healthcare practitioners, and decision-makers. Being the Immediate Past President of ISPOR Singapore, Dr. Allen shared topic on “Health Economics Issues in Precision Oncology”.

Image title

 Sep 21    ACT Genomics  Met up with Taiwan Trade Organisation in Ho Chi Minh City Oncology Hospital

ACT Genomics was honoured to participate Taiwan trade organization’s visit to the Ho Chi Minh city Oncology Hospital. Meeting up with the key leaders of the hospital to showcase Taiwan medical capabilities and explore possible future collaboration.

Image title

Sep 17    ACT Genomics Introduced Precision Medicine in Finland – Singapore HealthTech Exchange

ACT Genomics was honoured to be invited to share at Finland-Singapore HealthTech Exchange 2018. This event was organized by Ambassador of Finland in partnership with Business Finland, City of Helsinki and Finnish national innovation program "Personalized Health Program". Participants were Finnish companies with new solutions for healthcare needs and experts from universities and public sector organizations that interested in potential collaborations in health and wellness with Singaporean and Southeast Asian partners.

Image title

Sep 17     Scientific Talk at ARC Hospitals Grand Opening

Congratulations to Allegiant Regional Care (ARC) Hospitals on their official opening in Barangay Agus, Lapu-Lapu City! ACT Genomics was very honoured to be invited to conduct the first scientific talk with the oncologists and medical officers sharing topic on “The Role of Comprehensive Genomic Profiling in Cancer Management in the Era of Precision Medicine”.

Image title

 Sep 11     Comprehensive Approach in Lung Cancer Treatment: Recent Therapeutic Advances and Genetic Tests

Dr. Lee Siu Hong’s medical talk was organized by Health Action and sponsored by ACT Genomics at the Hong Kong Cultural Centre. Dr. Lee pointed out despite lung cancer incidence rate showed a mild decrease in recent years, it remains one of the most lethal cancer types of all. Dr. Lee’s talk gave a thorough update on the recent advance in clinical management of lung cancers, especially the rapid development of targeted and immunotherapies that result in enhanced survival rates with minimal side effects. Dr. Lee also shared the benefit of applying next-generation sequencing (NGS) in guiding selection of targeted treatments as standard of care for different cancers. During Q&A session, multiple questions were raised about NGS, from guideline of the best time frame for undergoing a cancer profiling test, to the future trend of cancer monitoring for relapsed cancers. ACTG is thrilled about comprehensive cancer genome profiling technology becoming more widely known than ever.

Image title

 Sep 08    ACT Genomics HK enjoyed a weekend gathering with cancer patients and oncology nurse in Macau

On September 8th, ACT Genomics Hong Kong was invited to a Saturday gathering with cancer patients and oncology nurses of Macau Associação de Feliz Paraíso, one of the most well-established cancer associations in Macau. The Associação de Feliz Paraíso is organized by a group of cancer patients, together with their families, local healthcare professionals and social workers, who share the same vision in promoting cancer awareness. The gathering was rewarding and allowed proactive exchange of different views on how cancer patients can benefit from precision diagnostics and comprehensive cancer profiling tests via NGS. It was a valuable afternoon to explore how ACTG can form synergistic partnerships with NGOs and social welfare departments, publicizing our mission on cancer care through precision medicine, working towards preventing and tackling cancers together.

Image title

 Sep 07   Lab Director of ACT Genomics HK Delivered an Educational Lecture on NGS Application to Guide Targeted Therapeutics through Cancer Genomic Profiling

Dr. Timothy Yip, Lab Director of ACT Genomics Hong Kong, was invited to give a lecture on the application of next-generation sequencing (NGS) to guide targeted therapeutics through cancer genomic profiling. Approximately 20 Scientific Officers of the public sector entity participated this professional training program "Recent Advances in Methodology, Tools and Applications of R & D in Laboratory Medicine" organized by Hospital Authority and Institute of Advanced Allied Health Studies. Most participants are experienced in the clinical utility of NGS platform in the prenatal and neonatal screening and through this lecture the application of NGS technology to guide cancer treatment, including cancer relapse and drug resistance monitoring, as well as cancer risk assessment and immunotherapy evaluation were introduced.

Image title


Sep 06   ACTG HK Invited to Share Insights and Experiences at Hong Kong-Taiwan Economic Co-operation Forum “Seizing New Opportunities of Biotechnology, Collaborating to Win the Future"

On September 6th , ACT Genomics Hong Kong was invited to deliver a talk at “2018 Hong Kong-Taiwan Economic Co-operation Forum” in Taipei, jointly organized by Hong Kong Economic, Trade and Cultural Office in Taiwan (HKETCO) and “Business Today” . The forum invited experts of the biotechnology industry from Hong Kong and Taiwan as guest speakers to share their insights and experiences on the development of the biotechnology industry and how Hong Kong and Taiwan can generate business opportunities and facilitate industrial upgrading through mutually beneficial collaboration.
Mr. Eddie Liu, Managing Director of ACT Genomics Hong Kong was invited to give a talk to share the experience of ACT Genomics expanding from Taiwan to Hong Kong. He emphasized the competitive advantage of Taiwan in developing innovative technologies, while Hong Kong is in hope to become a city in Asia that offers a vibrant innovation and technology ecosystem with a mature financing environment. Mr. Liu also addressed that ACT Genomics considered Hong Kong as a city that gathers international business talents, together with its high standard medical system, is a conducive environment for biotech firms to expand and tap into the Greater China market, and even Asia.

Economic Daily-Hong Kong and Taiwan cooperate on new opportunities in Biotechnology : https://money.udn.com/money/story/5636/3364205

Economic Daily- Open up new innovations in biotechnology from Taiwan, Hong Kong to Mainland China : https://money.udn.com/money/story/5636/3364209

Image title

Finding New Drug through Cancer Genomic Profiling is The New Option for Cancer Treatment 

A patient with advanced colon cancer was eager to find new drugs to avoid continuous cancer relapse, and he accepted comprehensive cancer genomic profiling after discussing with medical team in St. Martin De Porres Hospital.  PI3K-mTOR signaling pathway was detected with genetic mutations when analyzing 440 cancer-related genes, and two targeted drugs were used to control cancer growth.  Dr. Hsiao from St. Martin De Porres Hospital also reminds cancer patient to accept genomic profiling at an early stage for better treatment. 


Image title

Niraparib Shows Promise in Recurrent Ovarian Cancer with Homologous Recombinant Deficiency

Abstract : In the phase 2 QUADRA study, niraparib showed durable antitumor activity in patients with advanced, relapsed, high-grade serous epithelial ovarian cancer.    See more...

Image title

STK11/LKB1 Mutations Confer Resistance to Immune Checkpoint Inhibitors in NSCLC

Abstract : In two recently published studies, immune checkpoint inhibitors showed inferior clinical outcome in NSCLC patients carrying STK11 mutations.   See more...

Image title

Refametinib/Sorafenib Combo Improves Survival in RAS-Mutated Hepatocellular Carcinoma

Abstract : Two phase 2 studies showed that the combination of refametinib and sorafenib improved overall survival (OS) and objective response rate (ORR) in patients with RAS-mutated hepatocellular carcinoma (HCC).     See more...

Image title

Capmatinib Plus Gefitinib is Active in MET-dysregulated NSCLC

Abstract : A phase Ib/II study shows that the combination of capmatinib with gefitinib is a promising treatment for patients with EGFR-mutated, MET-dysregulated NSCLC.  See more...

Image title

Genome Editing Tool Helps Classification of BRCA1 Variants More Accurate

Abstract : Researchers in the University of Washington applied genome editing to measure nearly 4,000 single-nucleotide variants (SNVs) in 13 exons that are associated with BRCA1 functional domains. They identified more than 400 missense variants that would make BRCA1 lose its function. In addition, about 300 SNVs that would disrupt expression.     See more...

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :